32.68
price up icon3.98%   1.25
pre-market  プレマーケット:  33.16   0.48   +1.47%
loading
前日終値:
$31.43
開ける:
$31.62
24時間の取引高:
1.49M
Relative Volume:
1.06
時価総額:
$5.16B
収益:
$803.07M
当期純損益:
$-358.81M
株価収益率:
-13.39
EPS:
-2.44
ネットキャッシュフロー:
$-374.21M
1週間 パフォーマンス:
-0.03%
1か月 パフォーマンス:
-8.28%
6か月 パフォーマンス:
-31.66%
1年 パフォーマンス:
-35.90%
1日の値動き範囲:
Value
$31.47
$32.95
1週間の範囲:
Value
$31.40
$33.90
52週間の値動き範囲:
Value
$31.40
$52.49

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
名前
Ionis Pharmaceuticals Inc
Name
セクター
Healthcare (1176)
Name
電話
(760) 931-9200
Name
住所
2855 GAZELLE COURT, CARLSBAD, CA
Name
職員
927
Name
Twitter
@ionispharma
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
IONS's Discussions on Twitter

IONS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
IONS
Ionis Pharmaceuticals Inc
32.68 5.16B 803.07M -358.81M -374.21M -2.44
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-08-02 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-07-24 アップグレード Leerink Partners Market Perform → Outperform
2024-07-16 再開されました Jefferies Buy
2024-06-14 アップグレード Bernstein Underperform → Mkt Perform
2024-04-10 アップグレード Wolfe Research Peer Perform → Outperform
2024-01-02 アップグレード BofA Securities Neutral → Buy
2023-10-23 アップグレード BofA Securities Underperform → Neutral
2023-09-29 開始されました Raymond James Strong Buy
2023-07-31 アップグレード Citigroup Neutral → Buy
2023-06-07 再開されました Piper Sandler Overweight
2023-05-04 アップグレード Citigroup Sell → Neutral
2023-03-21 開始されました Bernstein Underperform
2022-12-21 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-09-09 再開されました Morgan Stanley Overweight
2022-07-18 再開されました Oppenheimer Outperform
2022-03-31 再開されました Piper Sandler Overweight
2022-03-01 開始されました Citigroup Sell
2022-03-01 開始されました Guggenheim Buy
2022-02-01 ダウングレード BofA Securities Buy → Underperform
2021-12-14 アップグレード William Blair Mkt Perform → Outperform
2021-05-07 アップグレード UBS Sell → Neutral
2021-03-01 アップグレード Barclays Underweight → Equal Weight
2020-12-16 開始されました UBS Sell
2020-12-15 アップグレード Cowen Market Perform → Outperform
2020-09-14 再開されました JP Morgan Neutral
2020-09-02 開始されました The Benchmark Company Hold
2020-06-01 再開されました Oppenheimer Outperform
2020-05-13 開始されました RBC Capital Mkts Outperform
2020-03-05 開始されました Citigroup Buy
2019-12-13 開始されました Oppenheimer Outperform
2019-11-13 開始されました BofA/Merrill Buy
2019-11-07 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-09-10 アップグレード Bernstein Mkt Perform → Outperform
2018-08-08 繰り返されました Stifel Hold
2018-08-07 繰り返されました Stifel Hold
2018-05-08 ダウングレード Evercore ISI Outperform → In-line
2017-10-06 再開されました Goldman Sell
2017-08-17 開始されました Evercore ISI Outperform
2017-08-09 繰り返されました Stifel Hold
2017-03-10 ダウングレード Goldman Neutral → Sell
2016-12-28 繰り返されました BMO Capital Markets Outperform
2016-12-27 繰り返されました Leerink Partners Mkt Perform
すべてを表示

Ionis Pharmaceuticals Inc (IONS) 最新ニュース

pulisher
Jan 21, 2025

Assenagon Asset Management S.A. Purchases 128,619 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Jan 21, 2025
pulisher
Jan 19, 2025

Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock - MSN

Jan 19, 2025
pulisher
Jan 19, 2025

Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock - MSN

Jan 19, 2025
pulisher
Jan 19, 2025

Ionis Pharmaceuticals CEO Brett Monia sells $1.09 million in stock - MSN

Jan 19, 2025
pulisher
Jan 18, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze Sells 7,154 Shares - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

Brett P. Monia Sells 33,445 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

Ionis Pharmaceuticals CFO sells stock worth $290,989 - MSN

Jan 18, 2025
pulisher
Jan 18, 2025

Ionis Pharmaceuticals exec sells $144,861 in stock By Investing.com - Investing.com Australia

Jan 18, 2025
pulisher
Jan 18, 2025

Ionis Pharmaceuticals EVP sells $232,407 in stock By Investing.com - Investing.com Australia

Jan 18, 2025
pulisher
Jan 18, 2025

Ionis Pharmaceuticals EVP sells $213,889 in stock - MSN

Jan 18, 2025
pulisher
Jan 18, 2025

Ionis Pharmaceuticals EVP sells $232,407 in stock - MSN

Jan 18, 2025
pulisher
Jan 17, 2025

Ionis Pharmaceuticals exec sells $144,861 in stock - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Ionis Pharmaceuticals EVP sells $241,628 in stock - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock By Investing.com - Investing.com Australia

Jan 17, 2025
pulisher
Jan 17, 2025

Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 17, 2025

Ionis Pharmaceuticals CFO sells stock worth $290,989 By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 17, 2025

EVP, Chf Clinical Develop Ofcr Schneider Eugene converted options into 17,372 shares and sold $213,889 worth of shares (6,523 units at $32.79), increasing direct ownership by 23% to 58,508 units (SEC Form 4) - Quantisnow

Jan 17, 2025
pulisher
Jan 17, 2025

Ionis Pharmaceuticals EVP sells $213,889 in stock By Investing.com - Investing.com UK

Jan 17, 2025
pulisher
Jan 17, 2025

Ionis Pharmaceuticals EVP sells shares worth $139,855 By Investing.com - Investing.com UK

Jan 17, 2025
pulisher
Jan 17, 2025

Director Yang Michael J. converted options into 1,931 shares (SEC Form 4) - Quantisnow

Jan 17, 2025
pulisher
Jan 17, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month LowTime to Sell? - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Why Ionis Pharmaceuticals (IONS) Is the Biotech Stock with Biggest Upside Potential - Insider Monkey

Jan 17, 2025
pulisher
Jan 17, 2025

Familial Lipoprotein Lipase Deficiency Market to Continue - openPR

Jan 17, 2025
pulisher
Jan 15, 2025

Retinitis Pigmentosa Pipeline Assessment 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics, ID Pharma - Barchart

Jan 15, 2025
pulisher
Jan 15, 2025

Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail

Jan 15, 2025
pulisher
Jan 15, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Receives Outperform Rating from Royal Bank of Canada - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

U.S, Europe And GCC Antisense Oligonucleotide (ASO) - openPR

Jan 14, 2025
pulisher
Jan 13, 2025

Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Ionis enters new chapter in 2025 as commercial-stage biotech wit - GuruFocus.com

Jan 13, 2025
pulisher
Jan 13, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by International Assets Investment Management LLC - MarketBeat

Jan 13, 2025
pulisher
Jan 10, 2025

Ionis Pharma stock hits 52-week low at $33.33 amid market challenges - Investing.com Australia

Jan 10, 2025
pulisher
Jan 10, 2025

US FDA approves Ionis Pharma's genetic disorder drug - AOL

Jan 10, 2025
pulisher
Jan 10, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Sets New 1-Year LowShould You Sell? - MarketBeat

Jan 10, 2025
pulisher
Jan 09, 2025

Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.

Jan 09, 2025
pulisher
Jan 09, 2025

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference - The Malaysian Reserve

Jan 09, 2025
pulisher
Jan 08, 2025

Vanguard Group Inc's Strategic Acquisition of Ionis Pharmaceuticals Shares - GuruFocus.com

Jan 08, 2025
pulisher
Jan 08, 2025

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conferenc - GuruFocus.com

Jan 08, 2025
pulisher
Jan 08, 2025

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times

Jan 08, 2025
pulisher
Jan 08, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Jan 08, 2025
pulisher
Jan 07, 2025

Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected - Benzinga

Jan 07, 2025
pulisher
Jan 06, 2025

Otsuka and Ionis’ donidalorsen accepted for EMA review - The Pharma Letter

Jan 06, 2025
pulisher
Jan 05, 2025

Objective long/short (IONS) Report - Stock Traders Daily

Jan 05, 2025
pulisher
Jan 03, 2025

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic - Benzinga

Jan 03, 2025
pulisher
Dec 31, 2024

Ionis Pharmaceuticals Initiates Phase 3 Study of Olezarsen to Treat Severe Hypertriglyceridemia - Marketscreener.com

Dec 31, 2024
pulisher
Dec 27, 2024

Ionis Pharmaceuticals director Hayden buys $181k in stock By Investing.com - Investing.com Australia

Dec 27, 2024

Ionis Pharmaceuticals Inc (IONS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
大文字化:     |  ボリューム (24 時間):